Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

San Francisco, USA
201 Mission Street
Suite 1380
San Francisco, CA, 94105
USA

People

COO
President & CEO & Board of Directors
Vice President of Finance & Corporate Development
Vice President of Quality Assurance & Regulatory Affairs
Vice President of Clinical Research
VP of Product Development
Board of Directors
Board of directors
Show All People

Funding

TOTAL $46.1M
FUNDING TOTAL $46.1M
Series C, 9/2009
Ottawa Regional Cancer Foundation
$5.5M
Series D, 10/2010
$8.6M
Venture Round, 8/2011
$8.6M
Seed, 10/2011
$1.75M
Private Equity, 5/2013
$21.6M

Tags

Jennerex Biotherapeutics

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company’s lead product JX-594, currently in an international Phase 2 trial for primary liver cancer and colorectal cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.

Recent Milestones

Videos

Screenshots

Jennerex Biotherapeutics screenshot
Above: Jennerex Biotherapeutics
Uploaded: 9/22/09

Sources

  1. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million (jennerex.com) [edit]
  2. Jennerex Biotherapeutics, Inc.: Series D $8.6M (onbiovc.com) [edit]
  3. Jennerex Completes $8.6M Financing (finsmes.com) [edit]
  4. SEC (sec.gov) [edit]
  5. Jennerex Biotherapeutics Raises $21.6M for Cancer Therapy (pevc.dowjones.com) [edit]
  6. Transgene teams with Jennerex in $116M cancer pact (fiercebiotech.com) [edit]
Edit This Page
Last Edited 11/5/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy